ArticleJournal of hepatocellular carcinoma2026
SEMA4F Regulates the Malignant Phenotype of Hepatocellular Carcinoma Cells Through the PI3K-Akt Pathway.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) is the most common pathological type of liver cancer. SEMA4F is an immune-related gene associated with HCC survival. As a transmembrane semaphorin, semaphorin 4F plays a key role in various biological processes. Recent studies have found that semaphorin 4F is closely related to cancer progression, but its role in HCC remains unclear. In this study, we aimed to investigate the function and related mechanisms of SEMA4F in HCC. Methods: Public databases were used to analyze the expression and prognosis of SEMA4F in HCC. Overexpression/knockdown cell models were constructed via lentiviral transfection/siRNA technology. The function of SEMA4F was explored through in vitro cellular experiments. Transcriptome sequencing was employed to investigate its molecular mechanisms, and Western blot was used to validate the expression of pathway proteins. Results: SEMA4F expression was elevated in tumor tissues of HCC patients and was associated with poor prognosis and shorter overall survival. In vitro analyses showed that SEMA4F overexpression promoted the proliferation, invasion, and migration of HCC cells, while SEMA4F knockdown led to the opposite phenotype. Furthermore, SEMA4F partially promoted HCC cell proliferation, migration, and invasion by activating the PI3K-Akt pathway; inhibition of this pathway significantly attenuated the pro‑proliferative, migratory, and invasive effects of SEMA4F. Conclusion: Our study reveals the function of SEMA4F in HCC. These findings suggest that SEMA4F is a potential prognostic biomarker for HCC and exerts pro‑cancer effects through activation of the PI3K-Akt pathway. These findings suggest SEMA4F as a potential therapeutic target, pending in vivo validation and clinical investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.